Cagrilintide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Cagrilintide

Also known as: Cagri, 0833, CagriSema (combination with semaglutide), DACRA (dual amylin and calcitonin receptor agonist)

Long-acting amylin analogue; dual amylin receptor (AMYR) and calcitonin receptor (CTR) agonist (DACRA)

Research chemicalLast updated: November 4, 2026Based on 24 peer-reviewed studies

What it is

Cagrilintide is an experimental weight-loss drug being studied in combination with semaglutide for obesity and type 2 diabetes. It mimics amylin, a hormone that signals fullness after eating, working alongside GLP-1 pathways to reduce appetite and body weight. Not FDA-approved; Phase 3 clinical trials ongoing.

The scientific side

Cagrilintide is a lipidated, long-acting amylin analogue engineered for once-weekly subcutaneous dosing. It functions as a dual agonist at amylin receptors (AMYRs) and the calcitonin receptor (CTR), activating Gs signalling pathways through both receptor types. Structurally, cagrilintide adopts a similar "bypass" binding mode in both receptors, with key molecular features including an F23 residue anchoring the peptide at the receptor transmembrane bundle, an E14–R17 intramolecular salt bridge enhancing helical stability, and a C-terminal P37 interaction with the receptor extracellular domain. These features collectively enable non-selective binding and activation across both receptor types. In the central nervous system, long-term cagrilintide treatment upregulates prolactin-releasing hormone (Prlh) expression in nucleus of the solitary tract Calcr/Prlh neurons; knockdown of DVC Prlh abrogates the effects of cagrilintide (but not semaglutide) on body weight in rats. Amylin and its analogues promote satiation, slow gastric emptying, suppress glucagon secretion, and influence both homeostatic and hedonic feeding mechanisms via central nervous system pathways. When combined with semaglutide (a GLP-1 receptor agonist) as CagriSema, the two agents act through complementary but distinct pathways, producing additive or synergistic effects on weight loss and glycaemic control.

Class: Long-acting amylin analogue; dual amylin receptor (AMYR) and calcitonin receptor (CTR) agonist (DACRA)

Administration & storage

Administration
Subcutaneous injectiononce-weekly (PMID: 34798060)Subcutaneous injectiononce-weeklyself-administered (PMID: 34798060)Subcutaneous injectiononce-weekly in combination with semaglutide 2.4 mg (PMID: 33894838)Subcutaneous injectiononce-weekly as fixed-dose combination CagriSema (PMID: 405444334054443142251859422518604225185642009015)
Storage
No storage conditions for cagrilintide are described in the reviewed abstracts. The potential for amyloid fibril aggregation in amylin-based peptide therapeutics is noted as a formulation consideration requiring proper storage, manipulation, and usage to avoid high-molecular-weight products.
Cautions
Gastrointestinal adverse events (nausea, vomiting, constipation, diarrhoea) were the most frequently reported adverse events across all clinical studies of cagrilintide, occurring in 41–63% of cagrilintide monotherapy recipients vs 32% with placebo in the phase 2 dose-finding trial.,Gastrointestinal adverse events were more common with CagriSema than with semaglutide or placebo; GI AE-related discontinuation was highest with high-dose CagriSema among novel amylin-based therapies in network meta-analysis.,Administration-site conditions were significantly more frequent with CagriSema combination therapy vs semaglutide monotherapy (RR 3.27; 95% CI 1.27–8.46).,Cagrilintide monotherapy was associated with a higher risk of serious adverse events compared to semaglutide monotherapy in a meta-analysis (RR 1.83; 95% CI 1.03–3.24).,Amylin-based therapeutic peptides may be prone to high-molecular-weight product (amyloid/amorphous) formation; proper formulation and handling are important to preserve biological activity and avoid immune reactions.,Cagrilintide did not produce clinically relevant QTc prolongation at doses up to 4.5 mg in a dedicated thorough QT study, indicating no identified increased risk of ventricular tachyarrhythmias.,No dose adjustment appears required for renal or hepatic impairment based on pharmacokinetic studies, though sample sizes were small.,Sterile technique is required for all subcutaneous injections to prevent injection-site contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Semaglutide has been included in the World Anti-Doping Agency's monitoring program since 2024; cagrilintide is noted to warrant consideration for anti-doping monitoring programs but its current WADA status is not…

Health Canada

Not stated in reviewed literature — requires manual verification